Contributions of active site residues to the partial and overall catalytic activities of human S-adenosylhomocysteine hydrolase

被引:20
作者
Elrod, P
Zhang, JS
Yang, XD
Yin, D
Hu, YB
Borchardt, RT
Schowen, RL [1 ]
机构
[1] Univ Kansas, Dept Mol Biosci, Simons Res Lab, Lawrence, KS 66047 USA
[2] Univ Kansas, Dept Pharmaceut Chem, Simons Res Lab, Lawrence, KS 66047 USA
关键词
D O I
10.1021/bi025771p
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Residues glutamate 156 (E156), aspartate 190 (D190), asparagine 181 (N181), lysine 186 (K186), and asparagine 191 (N191) in the active site of S-adenosylhomocysteine (AdoHcy) hydrolase have been mutated to alanine (A). AdoHcy hydrolase achieves catalysis of AdoHcy hydrolysis to adenosine (Ado) and homocysteine (Hcy) by means of a redox partial reaction (3'-oxidation of AdoHcy at the beginning and 3'-reduction of Ado at the end of the catalytic cycle) spanning an elimination/addition partial reaction (elimination of Hey from the oxidized substrate and addition of water to generate the oxidized product), with the enzyme in an open NAD(+) form in the ligand-free state and in a closed NADH form during the elimination/addition partial reaction. Mutation K186A reduces the rate of a model enzymatic reaction for the redox partial reaction by a factor of 280000 and the rate of a model reaction for the elimination/addition partial reaction by a factor of 24000, consistent with a primary catalytic role in both partial reactions as a proton donor/acceptor at the 3'-OH/3'-keto center. Secondary roles for N181 and N191 in localizing the flexible side chain of K186 in a catalytically effective position are supported by rate reduction factors for N181A of 2500 (redox) and 240 (elimination/addition) and for N191A of 730 (redox) and 340 (elimination/addition). A role of D190 in orienting the substrate for effective transition-state stabilization is consistent with rate reduction factors of 1300 (redox) and 30 (elimination/addition) for D190A. Residue E156 may act to maintain K186 in the desired protonation state: rate deduction factors are 1100 (redox) and 70 (elimination/addition). The mutational increases in free energy barriers for k(cat)/K-M are described by a linear combination of the effects for the partial reactions with the coefficients equal to the fractional degree that each partial reaction determines the rate for k(cat)/K-M. A similar linear equation for k(cat) overestimates the barrier increase by a uniform 5 kJ/mol, probably reflecting reactant-state stabilization by the wild-type enzyme that is abolished by the mutations.
引用
收藏
页码:8134 / 8142
页数:9
相关论文
共 21 条
[1]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[2]   Biological effects of inhibitors of S-adenosylhomocysteine hydrolase [J].
Chiang, PK .
PHARMACOLOGY & THERAPEUTICS, 1998, 77 (02) :115-134
[3]   SEQUENCE OF FULL LENGTH CDNA FOR HUMAN S-ADENOSYLHOMOCYSTEINE HYDROLASE [J].
COULTERKARIS, DE ;
HERSHFIELD, MS .
ANNALS OF HUMAN GENETICS, 1989, 53 :169-175
[4]   Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase [J].
Guillerm, G ;
Guillerm, D ;
Vandenplas-Witkowki, C ;
Rogniaux, H ;
Carte, N ;
Leize, E ;
Van Dorsselaer, A ;
De Clercq, E ;
Lambert, C .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (17) :2743-2752
[5]   S-ADENOSYLHOMOCYSTEINE HYDROLASE FROM HUMAN-PLACENTA - AFFINITY PURIFICATION AND CHARACTERIZATION [J].
HERSHFIELD, MS ;
AIYAR, VN ;
PREMAKUMAR, R ;
SMALL, WC .
BIOCHEMICAL JOURNAL, 1985, 230 (01) :43-52
[6]   Crystal structure of S-adenosylhomocysteine hydrolase from rat liver [J].
Hu, YB ;
Komoto, J ;
Huang, Y ;
Gomi, T ;
Ogawa, H ;
Takata, Y ;
Fujioka, M ;
Takusagawa, F .
BIOCHEMISTRY, 1999, 38 (26) :8323-8333
[7]   Inhibition of S-adenosylhomocysteine hydrolase by acyclic sugar adenosine analogue D-eritadenine -: Crystal structure of S-adenosylhomocysteine hydrolase complexed with D-eritadenine [J].
Huang, YF ;
Komoto, J ;
Takata, Y ;
Powell, DR ;
Gomi, T ;
Ogawa, H ;
Fujioka, M ;
Takusagawa, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (09) :7477-7482
[8]  
MATUSZEWSKA B, 1987, J BIOL CHEM, V262, P265
[9]   Total homocysteine and cardiovascular disease [J].
Nygård, O ;
Vollset, SE ;
Refsum, H ;
Brattström, L ;
Ueland, PM .
JOURNAL OF INTERNAL MEDICINE, 1999, 246 (05) :425-454
[10]  
PALMER JL, 1979, J BIOL CHEM, V254, P1217